Hyperoncotic colloids and acute kidney injury: A meta-analysis of randomized trials

Department of Internal Medicine, Central Hospital of Bolzano, Lorenz Böhler Street 5, 39100 Bolzano, Italy.
Critical care (London, England) (Impact Factor: 4.48). 10/2010; 14(5):R191. DOI: 10.1186/cc9308
Source: PubMed


It has been hypothesized that hyperoncotic colloids might contribute to acute kidney injury (AKI). However, the validity of this hypothesis remains unclear.
A meta-analysis was conducted of randomized controlled trials evaluating AKI after infusion of hyperoncotic albumin and hydroxyethyl starch (HES) solutions. Mortality was a secondary endpoint. Eligible trials were sought by multiple methods, and the pooled odds ratios (OR) for AKI and death and 95% confidence intervals (CI) were computed under a random effects model.
Eleven randomized trials with a total of 1220 patients were included: 7 evaluating hyperoncotic albumin and 4 hyperoncotic HES. Clinical indications were ascites, surgery, sepsis and spontaneous bacterial peritonitis. Hyperoncotic albumin decreased the odds of AKI by 76% (OR, 0.24; CI, 0.12-0.48; P < 0.0001), while hyperoncotic HES increased those odds by 92% (OR, 1.92; CI, 1.31-2.81; P = 0.0008). Parallel effects on mortality were observed, with hyperoncotic albumin reducing the odds of death by 48% (OR, 0.52; CI, 0.28-0.95; P = 0.035) and hyperoncotic HES raising those odds by 41% (OR, 1.41; CI, 1.01-1.96; P = 0.043).
This meta-analysis does not support the hypothesis that hyperoncotic colloid solutions per se injure the kidney. Renal effects appear instead to be colloid-specific, with albumin displaying renoprotection and HES showing nephrotoxicity.

Download full-text


Available from: Christian Josef Wiedermann, Apr 15, 2014
41 Reads
  • Source
    • "7. The type of administered fluid. A recent meta-analysis [81] of randomised trials supported the hypothesis that albumin is nephroprotective, and hydroxyethyl starch is nephrotoxic. Albumin reduces renal dysfunction and death, particularly in cirrhotic patients with spontaneous peritonitis [50]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Although associated with low morbidity and mortality, cardiopulmonary bypass remains a "non-physiologic" device that carries a set of complications. Hepatic and renal impairment are associated with a poor outcome. The knowledge of pathophysiology, risk factors and therapeutic interventions can help the anaesthesiologist in preventing these complications in daily practice. The present narrative review provides an update of the literature on the effects of cardiopulmonary bypass on hepatic and renal functions, focussing on markers of hepatic and renal injuries, perioperative strategies in preserving organ function and replacement therapies. Copyright © 2015 Elsevier Ltd. All rights reserved.
    Baillière&#x27 s Best Practice and Research in Clinical Anaesthesiology 04/2015; 29(2). DOI:10.1016/j.bpa.2015.04.001
  • Source
    • "La tonicità di preparazioni colloidali può anche variare a seconda dell'agente. Una recente meta-analisi [32] [32] (full text) ha descritto 11 studi randomizzati per un totale di 1.220 pazienti: sette valutano l'effetto dell'albumina iperoncotica e quattro degli amidi iperoncotici. L'utilizzo di albumina iperoncotica si è associata alla diminuzione di probabilità di sviluppare AKI del 76%, a differenza di quella riportata dagli amidi iperoncotici, 92% (odds ratio [OR] 1.92; CI 1,31-2,81, p =0.0008). "
    03/2015; 32(2).
  • Source
    • "Nevertheless, the findings of a recent single-center, sequential, observational study [41], indicating that chloride-rich fluids, including saline and albumin, were associated with increased renal injury and need for RRT in ICU patients is of interest and should inform future further trials allowing this issue to discriminate further between individual fluids than did this sequential study, which, because of its particular design, did not lend itself to incorporation into our NMA. Since the available evidence continues to indicate a lack of adverse renal effects from albumin [37], it is likely that the burden of renal injury observed by Yunos et al. was caused by other chloride-rich fluids, the use of which cannot be considered to be cost-effective if further studies confirm Yunos et al’s results. Formulations of albumin in balanced salt solutions would be needed to address directly this issue, and it is unlikely that such products will be available, or needed, for trial in the foreseeable future. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Fluid resuscitation with colloids is an established second line therapy for septic patients. Evidence of relative efficacy outcomes is tempered by considerations of the relative costs of the individual fluids. An assessment of recent large clinical trials was performed, resulting in a ranking in the efficacy of these therapies. Probabilities for mortality and the need for renal replacement therapy (RRT) were derived and used to inform a decision analysis model comparing the effect of crystalloid, albumin and hydroxyethyl starch solutions in severe septic patients followed from hospital admission to 90 days in intensive care. The US payer perspective was used. Model inputs for costs and efficacy were derived from the peer-reviewed literature, assuming that that all fluid preparations are bio-equivalent within each class of these therapies. Probabilities for mortality and the need for renal replacement therapy (RRT) data were synthesized using a Bayesian meta-analysis. Relative to crystalloid therapy, 0.22 life years were gained with albumin and 1.00 life years were lost with hydroxyethyl starch. One-way sensitivity analysis showed that the model's outcomes were sensitive to the cost of RRT but not to the costs of the actual fluids or any other costs. We conclude that albumin may be the most cost-effective treatment in these patients when the total medical costs and iatrogenic morbidities involved in treating sepsis with fluids are considered. These results should assist and inform decision making in the choice of these drugs.
    Reviews on Recent Clinical Trials 12/2013; 9(1). DOI:10.2174/1574887108666131213120816 · 1.07 Impact Factor
Show more